Literature DB >> 25186219

Iron sucrose - characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas.

Yves Beguin1, Aurélie Jaspers.   

Abstract

INTRODUCTION: Iron is a key element in the transport and utilization of oxygen and a variety of metabolic pathways. Iron deficiency is a major cause of anemia and can be associated with fatigue, impaired physical function and reduced quality of life. Administration of oral or intravenous (i.v.) iron is the recommended treatment for iron-deficiency anemia (IDA) in different therapeutic areas. AREAS COVERED: This article provides an overview of studies that evaluated i.v. iron sucrose for anemia and iron status management, either alone or in combination with erythropoiesis-stimulating agents, across various diseases and conditions. EXPERT OPINION: Iron sucrose is an established, effective and well-tolerated treatment of IDA in patients with acute or chronic conditions such as chronic kidney disease, inflammatory bowel disease, pregnancy (second and third trimester), postpartum period, heavy menstrual bleeding and cancer who need rapid iron supply and in whom oral iron preparations are ineffective or not tolerated. Available data on patient blood management warrant further studies on preoperative iron treatment. First experience with iron sucrose follow-on products raises questions about their therapeutic equivalence without comparative clinical data in newly diagnosed patients or patients on existing chronic treatment.

Entities:  

Keywords:  anemia; efficacy; follow-on products; generics; iron deficiency; iron sucrose; pharmacodynamics; pharmacokinetics; safety; substitution; tolerability

Mesh:

Substances:

Year:  2014        PMID: 25186219     DOI: 10.1517/14656566.2014.953928

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  9 in total

1.  Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study).

Authors:  Elisabeth Luporsi; Alain Toledano; Dominique Spaeth; Florian Scotté; Marc Espié; Stéphanie Perot; Ladan Duvillié; Isabelle Pithois Merli; Roland Bugat
Journal:  Support Care Cancer       Date:  2016-12-03       Impact factor: 3.603

2.  A fast-track anaemia clinic in the Emergency Department: feasibility and efficacy of intravenous iron administration for treating sub-acute iron deficiency anaemia.

Authors:  Manuel Quintana-Díaz; Sara Fabra-Cadenas; Susana Gómez-Ramírez; Ana Martínez-Virto; José A García-Erce; Manuel Muñoz
Journal:  Blood Transfus       Date:  2015-11-19       Impact factor: 3.443

Review 3.  Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?

Authors:  Donald S Silverberg; Dov Wexler; Doron Schwartz
Journal:  Int J Mol Sci       Date:  2015-06-18       Impact factor: 5.923

Review 4.  Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients.

Authors:  Jolanta Malyszko; Stefan D Anker
Journal:  Clin Kidney J       Date:  2017-11-28

5.  Medication practice in hospitals: are nanosimilars evaluated and substituted correctly?

Authors:  Josefien Knoeff; Beat Flühmann; Stefan Mühlebach
Journal:  Eur J Hosp Pharm       Date:  2017-01-23

Review 6.  Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients.

Authors:  Alejandro Martin-Malo; Gerrit Borchard; Beat Flühmann; Claudio Mori; Donald Silverberg; Ewa A Jankowska
Journal:  ESC Heart Fail       Date:  2019-01-29

7.  Postoperative intravenously administered iron sucrose versus postoperative orally administered iron to treat post-bariatric abdominoplasty anaemia (ISAPA): the study protocol for a randomised controlled trial.

Authors:  Juan Carlos Montano-Pedroso; Elvio Bueno Garcia; Neil Ferreira Novo; Daniela Francescato Veiga; Lydia Masako Ferreira
Journal:  Trials       Date:  2016-04-12       Impact factor: 2.279

8.  Intravenous transfusion of iron sucrose reduces blood transfusions and improves postoperative anaemia after a second thoracotomy: a propensity-score matching study.

Authors:  Chentao Luo; Yunqing Shi; Yi Lin; Runhua Ma; Qi Xia; Wenjun Ding
Journal:  J Int Med Res       Date:  2020-02       Impact factor: 1.671

Review 9.  Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency.

Authors:  Iain C Macdougall; Josep Comin-Colet; Christian Breymann; Donat R Spahn; Ioannis E Koutroubakis
Journal:  Adv Ther       Date:  2020-04-15       Impact factor: 3.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.